A Clinico-Etiopathological Study to evaluate the efficacy of Kiratatikta Churna in the management of Amavata - A Single arm clinical Trial
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Reduction in VAS score and DAS28 Score is expected and will be assessed on 0, 15th, 30th and 45th day.
研究概览
简要总结
Amavata has been described as the disease having highest incurable tendency among all the disease as acharaya madhavkar says ( sa kashtah sarva roganaam yada prakupito bhaveta).
Amavata is a systemic disease where along with articular symptoms, manifestation of Gastrointestinal, cardiac and renal disturbances are also evident.Gastrointestinal changes are primary pathological factor for the development of this disease.
Rheumatoid arthritis is a autoimmune musculo-skeletal disorder, which leads to irreversible joint damage and systemic complication as explained in modern medicine
Ama is only responsible for the production of multiple symptoms and due to this ama the disease is considered difficult to treat as mentioned by acharaya madhavkar ( vyadhinam ashryo hi eshaam amasangyoatidarunaah).
The present study is aimed to find out the efficacy of Kiratatikta churna in the management of Amavata.
Study type is interventional and the study design is single arm clinical trial with sample size of 50 patients.
Kiratatikta churna will be given in the dose of 3gm with Ushnodaka , twice daily , after meal for 45 days.
This study is expected to be beneficial in the management of Amavata.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 20.00 Year(s) 至 55.00 Year(s)（—）
- 性别
- All
入选标准
- •Diagnosed Patients Of Rheumatoid Arthritis as per 2010 ACR/ EULAR Criteria Patients having Samanyalakshana and Pravridhhalakshana of Amavata as per Madhavnidana Patients willing to give consent for the study.
排除标准
- •Pregnant women and Lactating mothers All other forms of Arthritis Patients having co morbidities.
结局指标
主要结局
Reduction in VAS score and DAS28 Score is expected and will be assessed on 0, 15th, 30th and 45th day.
时间窗: 45 Days
次要结局
- The study will provide cost effective, safe drug with lesser side effects(6 months)